Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    Takeda Pharmaceutical Li...

    NYSE: TAK · Real-Time Price · USD
    15.06
    -0.14 (-0.92%)
    At close: Jun 16, 2025, 3:59 PM
    15.01
    -0.37%
    After-hours: Jun 16, 2025, 06:00 PM EDT
    -0.92%
    Bid 14.82
    Market Cap 47.41B
    Revenue (ttm) 4,546.1B
    Net Income (ttm) 290B
    EPS (ttm) 0.23
    PE Ratio (ttm) 65.5
    Forward PE 0.35
    Analyst n/a
    Ask 15.42
    Volume 1,584,428
    Avg. Volume (20D) 2,137,511
    Open 15.15
    Previous Close 15.20
    Day's Range 15.03 - 15.18
    52-Week Range 12.58 - 15.43
    Beta 0.26

    About TAK

    undefined

    [Read more]
    Industry n/a
    Sector n/a
    IPO Date n/a
    Employees NaN
    Stock Exchange n/a
    Ticker Symbol TAK
    Website n/a
    Full Company Profile

    Why Price Moved

    Why Price Moved is a one-sentence explanation of why a stock is moving higher or down. By removing noise and collecting signals from news, press releases and SEC filings, we can pinpoint the trigger for price movements.
    1 month ago
    -5.25%
    Takeda Pharmaceutical shares are trading lower fol... Unlock content with Pro Subscription
    3 months ago
    +2.98%
    Takeda Pharmaceutical shares are trading higher after the company announced topline results from phase 3 verify study of rusfertide in patients with polycythemia vera.
    news image

    1 week ago · businesswire.com

    European Commission Approves ADCETRIS® (brentuximab vedotin) for the Treatment of Adult Patients with Newly Diagnosed Stage IIb/III/IV Hodgkin Lymphoma in Combination with ECADD

    OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) today announced that the European Commission (EC) approved ADCETRIS® (brentuximab vedotin) in combination with etoposide, c...

    news image

    2 weeks ago · businesswire.com

    Protagonist and Takeda Announce ASCO Plenary Presentation Highlighting Full 32-Week Results from Phase 3 VERIFY Study of Rusfertide, Showing Reductions in Phlebotomy, Improved Hematocrit Control in Polycythemia Vera

    NEWARK, Calif. & OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announced detailed results from the Phase...

    news image

    2 weeks ago · businesswire.com

    Takeda and Nature Announce Call for Applications Now Open for 2026 Innovators in Science Award

    OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Applications are now open for the Takeda Innovators in Science Award with Nature recognizing the groundbreaking research of early-career scientists.

    news image

    1 month ago · businesswire.com

    The New England Journal of Medicine Publishes Data from Phase 2b Trial of Oral Orexin Receptor 2 Agonist Oveporexton (TAK-861) in People with Narcolepsy Type 1

    OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE: 4502/NYSE:TAK) today announced that the New England Journal of Medicine published data from the Phase 2b trial of oveporexton (TAK-861) i...

    news image

    1 month ago · seekingalpha.com

    Takeda Pharmaceuticals Caps A Strong Year, Guidance Suggests Dividend Is On The Rise

    Takeda Pharmaceuticals showed strong revenue and operating income growth in FY2024, despite challenges from Vyvanse generics and US insurance issues. New guidance for FY2025 is slightly lower due to e...

    news image

    1 month ago · zacks.com

    Top 4 GARP Stocks With Attractive PEG Ratios to Watch

    Here we present four high-growth GARP picks based on discounted PEG. These are PAK, FIVN, LTM and MFG.

    news image

    1 month ago · seekingalpha.com

    Takeda Pharmaceutical Company Limited (TAK) Q4 2024 Earnings Call Transcript

    Takeda Pharmaceutical Company Limited (NYSE:TAK ) Q4 2024 Results Conference Call May 8, 2025 6:00 AM ET Company Participants Christopher O'Reilly - Head, Investor Relations Christophe Weber - Preside...

    1 month ago · youtube.com

    Takeda Pharma less impacted by tariff, yen headwinds than other Japanese drugmakers: CEO

    Christophe Weber, CEO of Takeda Pharma, discusses the group's plans to invest $30 billion into its U.S. operations over the next five years, saying the U.S. market remain crucial for the Japanese drug...

    news image

    1 month ago · benzinga.com

    Japanese Pharma Company Takeda Expects Limited Exposure To US-China Tariffs

    Takeda Pharmaceutical Company Limited TAK reported a fiscal year 2024 net profit of 107.9 billion yen (around $709.86 million), down 25.1% year over year.

    news image

    1 month ago · businesswire.com

    Takeda Announces FY2024 Full Year Results and FY2025 Outlook Reflecting Growth & Launch Products Momentum, Strong Cash Flow Generation and Late-Stage Pipeline Progress

    OSAKA, Japan--(BUSINESS WIRE)--Takeda (TOKYO:4502/NYSE:TAK) today announced financial results for fiscal year 2024 (period ended March 31, 2025) with continued strong momentum in Growth & Launch Produ...

    Add to Watchlist